Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility...

Area of Science:

• Cardiology
• Medical Devices
• Clinical Research

Background:

• Atrial fibrillation increases stroke risk, necessitating anticoagulation or alternative therapies.
• The WATCHMAN FLX device offers a percutaneous option for left atrial appendage closure (LAAC).
• Post-approval studies are crucial for evaluating device performance in unselected patient populations.

Purpose of the Study:

• To assess the real-world effectiveness and safety of the WATCHMAN FLX device for LAAC.
• To evaluate procedural success, left atrial appendage (LAA) seal rates, and adverse event profiles.
• To analyze medication regimens and outcomes at 1-year follow-up.

Main Methods:

• The FLXibility Post-Approval Study enrolled 300 patients undergoing WATCHMAN FLX implantation.
• Data collection included procedural outcomes, TEE/CT imaging, and clinical events adjudicated by a committee.
• Follow-up occurred at 45-120 days and 1 year post-procedure.

Main Results:

• Successful implantation was achieved in 99.0% of patients.
• Core-lab adjudicated complete LAA seal was 88.2% at first follow-up.
• At 1 year, adverse event rates included all-cause death (10.8%), CV/unexplained death (5.1%), and stroke (2.0% total, all non-fatal).

Conclusions:

• The WATCHMAN FLX device exhibits excellent procedural success and high LAA seal rates in clinical practice.
• Low rates of thromboembolic events were observed, supporting its role in stroke risk reduction.
• The study validates the device's safety and efficacy in an unselected patient cohort.